
EU Approves TEVIMBRA® Plus Chemo as First-Line NPC Treatment
European Commission Approves TEVIMBRA® (Tislelizumab) with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma BeOne Medicines Ltd., a global biotechnology company dedicated to oncology innovation, today announced that the European Commission (EC) has granted marketing authorization for TEVIMBRA®…